Exact Sciences Corporation (EXAS)
USD 42.12
(-0.34%)
USD 42.12
(-0.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.32 Billion USD | 4.47% |
| 2022 | 3.18 Billion USD | -3.44% |
| 2021 | 3.29 Billion USD | 56.89% |
| 2020 | 2.1 Billion USD | 72.59% |
| 2019 | 1.21 Billion USD | 44.44% |
| 2018 | 843.08 Million USD | 978.91% |
| 2017 | 78.14 Million USD | 87.19% |
| 2016 | 41.74 Million USD | 11.5% |
| 2015 | 37.44 Million USD | 65.37% |
| 2014 | 22.64 Million USD | 100.16% |
| 2013 | 11.31 Million USD | -16.36% |
| 2012 | 13.52 Million USD | 0.49% |
| 2011 | 13.45 Million USD | -19.71% |
| 2010 | 16.76 Million USD | -14.65% |
| 2009 | 19.63 Million USD | 135.71% |
| 2008 | 8.33 Million USD | 0.29% |
| 2007 | 8.3 Million USD | -6.77% |
| 2006 | 8.91 Million USD | -32.62% |
| 2005 | 13.22 Million USD | -27.05% |
| 2004 | 18.12 Million USD | -19.26% |
| 2003 | 22.45 Million USD | 91.3% |
| 2002 | 11.73 Million USD | 183.95% |
| 2001 | 4.13 Million USD | 204.22% |
| 2000 | 1.35 Million USD | 295.1% |
| 1999 | 343.88 Thousand USD | -16.12% |
| 1998 | 410 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.24 Billion USD | -2.48% |
| 2024 Q3 | 3.53 Billion USD | 1.64% |
| 2024 Q2 | 3.48 Billion USD | 7.31% |
| 2023 Q2 | 3.29 Billion USD | 1.61% |
| 2023 FY | 3.32 Billion USD | 4.47% |
| 2023 Q4 | 3.32 Billion USD | 0.8% |
| 2023 Q3 | 3.29 Billion USD | 0.02% |
| 2023 Q1 | 3.24 Billion USD | 1.98% |
| 2022 Q3 | 3.19 Billion USD | -0.93% |
| 2022 Q1 | 3.23 Billion USD | -1.97% |
| 2022 Q4 | 3.18 Billion USD | -0.44% |
| 2022 FY | 3.18 Billion USD | -3.44% |
| 2022 Q2 | 3.22 Billion USD | -0.14% |
| 2021 Q2 | 3.16 Billion USD | 2.58% |
| 2021 Q4 | 3.29 Billion USD | 3.14% |
| 2021 FY | 3.29 Billion USD | 56.89% |
| 2021 Q3 | 3.19 Billion USD | 1.0% |
| 2021 Q1 | 3.08 Billion USD | 46.82% |
| 2020 FY | 2.1 Billion USD | 72.59% |
| 2020 Q1 | 1.92 Billion USD | 57.96% |
| 2020 Q2 | 1.95 Billion USD | 1.72% |
| 2020 Q3 | 2.01 Billion USD | 3.1% |
| 2020 Q4 | 2.1 Billion USD | 4.18% |
| 2019 Q3 | 1.01 Billion USD | -0.53% |
| 2019 Q2 | 1.01 Billion USD | 2.29% |
| 2019 FY | 1.21 Billion USD | 44.44% |
| 2019 Q4 | 1.21 Billion USD | 20.45% |
| 2019 Q1 | 993.6 Million USD | 17.85% |
| 2018 Q2 | 738.26 Million USD | 29.54% |
| 2018 Q3 | 792.84 Million USD | 7.39% |
| 2018 FY | 843.08 Million USD | 978.91% |
| 2018 Q1 | 569.89 Million USD | 629.31% |
| 2018 Q4 | 843.08 Million USD | 6.34% |
| 2017 Q3 | 60.03 Million USD | 43.26% |
| 2017 Q2 | 41.9 Million USD | 2.86% |
| 2017 Q1 | 40.74 Million USD | -2.41% |
| 2017 FY | 78.14 Million USD | 87.19% |
| 2017 Q4 | 78.14 Million USD | 30.16% |
| 2016 Q3 | 40.88 Million USD | 4.45% |
| 2016 Q1 | 35.45 Million USD | -5.3% |
| 2016 FY | 41.74 Million USD | 11.5% |
| 2016 Q4 | 41.74 Million USD | 2.11% |
| 2016 Q2 | 39.14 Million USD | 10.4% |
| 2015 Q3 | 32.7 Million USD | 16.07% |
| 2015 FY | 37.44 Million USD | 65.37% |
| 2015 Q4 | 37.44 Million USD | 14.48% |
| 2015 Q2 | 28.17 Million USD | 36.74% |
| 2015 Q1 | 20.6 Million USD | -8.99% |
| 2014 Q1 | 12.37 Million USD | 9.38% |
| 2014 FY | 22.64 Million USD | 100.16% |
| 2014 Q4 | 22.64 Million USD | 15.73% |
| 2014 Q3 | 19.56 Million USD | 51.23% |
| 2014 Q2 | 12.93 Million USD | 4.55% |
| 2013 Q1 | 10.85 Million USD | -19.71% |
| 2013 Q3 | 10.4 Million USD | 8.06% |
| 2013 Q4 | 11.31 Million USD | 8.7% |
| 2013 FY | 11.31 Million USD | -16.36% |
| 2013 Q2 | 9.63 Million USD | -11.31% |
| 2012 Q4 | 13.52 Million USD | 5.69% |
| 2012 FY | 13.52 Million USD | 0.49% |
| 2012 Q1 | 12.14 Million USD | -9.78% |
| 2012 Q2 | 12.05 Million USD | -0.69% |
| 2012 Q3 | 12.79 Million USD | 6.12% |
| 2011 Q2 | 14.6 Million USD | -2.33% |
| 2011 Q3 | 13.89 Million USD | -4.86% |
| 2011 Q4 | 13.45 Million USD | -3.16% |
| 2011 FY | 13.45 Million USD | -19.71% |
| 2011 Q1 | 14.95 Million USD | -10.78% |
| 2010 Q2 | 18.55 Million USD | -4.09% |
| 2010 Q4 | 16.76 Million USD | -7.76% |
| 2010 Q1 | 19.35 Million USD | -1.66% |
| 2010 FY | 16.76 Million USD | -14.65% |
| 2010 Q3 | 18.17 Million USD | -2.09% |
| 2009 Q1 | 23.12 Million USD | 177.52% |
| 2009 Q2 | 21.97 Million USD | -4.96% |
| 2009 Q3 | 20.72 Million USD | -5.71% |
| 2009 Q4 | 19.67 Million USD | -5.04% |
| 2009 FY | 19.63 Million USD | 135.71% |
| 2008 Q4 | 8.33 Million USD | 6.89% |
| 2008 Q3 | 7.79 Million USD | 6.87% |
| 2008 Q2 | 7.29 Million USD | -3.95% |
| 2008 Q1 | 7.59 Million USD | -8.6% |
| 2008 FY | 8.33 Million USD | 0.29% |
| 2007 Q2 | 6.84 Million USD | -11.48% |
| 2007 Q4 | 8.3 Million USD | 16.51% |
| 2007 Q3 | 7.13 Million USD | 4.24% |
| 2007 Q1 | 7.72 Million USD | -13.28% |
| 2007 FY | 8.3 Million USD | -6.77% |
| 2006 Q2 | 10.98 Million USD | -6.88% |
| 2006 Q3 | 9.72 Million USD | -11.48% |
| 2006 Q4 | 8.91 Million USD | -8.35% |
| 2006 FY | 8.91 Million USD | -32.62% |
| 2006 Q1 | 11.79 Million USD | -10.81% |
| 2005 FY | 13.22 Million USD | -27.05% |
| 2005 Q2 | 15.21 Million USD | -5.48% |
| 2005 Q1 | 16.09 Million USD | -11.19% |
| 2005 Q3 | 14.08 Million USD | -7.46% |
| 2005 Q4 | 13.22 Million USD | -6.09% |
| 2004 Q2 | 20.52 Million USD | -5.85% |
| 2004 Q4 | 18.12 Million USD | -4.86% |
| 2004 Q1 | 21.79 Million USD | -2.92% |
| 2004 FY | 18.12 Million USD | -19.26% |
| 2004 Q3 | 19.05 Million USD | -7.15% |
| 2003 Q4 | 22.45 Million USD | -8.67% |
| 2003 Q1 | 10.99 Million USD | -6.31% |
| 2003 FY | 22.45 Million USD | 91.3% |
| 2003 Q2 | 10.38 Million USD | -5.59% |
| 2003 Q3 | 24.58 Million USD | 136.82% |
| 2002 FY | 11.73 Million USD | 183.95% |
| 2002 Q4 | 11.73 Million USD | -8.86% |
| 2002 Q3 | 12.87 Million USD | -3.45% |
| 2002 Q2 | 13.33 Million USD | 182.47% |
| 2002 Q1 | 4.72 Million USD | 14.23% |
| 2001 Q2 | 1.81 Million USD | 27.13% |
| 2001 Q3 | 2.91 Million USD | 61.07% |
| 2001 Q4 | 4.13 Million USD | 41.7% |
| 2001 Q1 | 1.42 Million USD | 0.0% |
| 2001 FY | 4.13 Million USD | 204.22% |
| 2000 FY | 1.35 Million USD | 295.1% |
| 1999 FY | 343.88 Thousand USD | -16.12% |
| 1998 FY | 410 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -8168.356% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -37785.482% |
| Aspira Women's Health Inc. | 8.62 Million USD | -38453.715% |
| Biodesix, Inc. | 94.51 Million USD | -3419.012% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -190838.097% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -98703.789% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -98703.789% |
| Bionano Genomics, Inc. | 118.24 Million USD | -2712.781% |
| CareDx, Inc | 223.28 Million USD | -1389.576% |
| Check-Cap Ltd. | 1.33 Million USD | -249977.368% |
| Castle Biosciences, Inc. | 86.54 Million USD | -3743.254% |
| DarioHealth Corp. | 38.24 Million USD | -8596.637% |
| Fulgent Genetics, Inc. | 139.82 Million USD | -2278.742% |
| Guardant Health, Inc. | 1.62 Billion USD | -104.335% |
| ICON Public Limited Company | 7.74 Billion USD | 57.079% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | -87.34% |
| Illumina, Inc. | 4.36 Billion USD | 23.82% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -59339.313% |
| iSpecimen Inc. | 6.07 Million USD | -54621.885% |
| Standard BioTools Inc. | 159.86 Million USD | -1980.524% |
| MDxHealth SA | 121.92 Million USD | -2627.953% |
| 23andMe Holding Co. | 206.64 Million USD | -1509.522% |
| Medpace Holdings, Inc. | 1.09 Billion USD | -202.951% |
| Myriad Genetics, Inc. | 312.9 Million USD | -962.969% |
| Mainz Biomed B.V. | 12.15 Million USD | -27252.658% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -303603.396% |
| NeoGenomics, Inc. | 739.69 Million USD | -349.651% |
| Neogen Corporation | 1.44 Billion USD | -130.971% |
| Inotiv, Inc. | 588.04 Million USD | -465.613% |
| Natera, Inc. | 691.79 Million USD | -380.78% |
| OpGen, Inc. | 13.44 Million USD | -24640.138% |
| OPKO Health, Inc. | 622.47 Million USD | -434.32% |
| Psychemedics Corporation | 6.59 Million USD | -50309.654% |
| Prenetics Global Limited | 44.01 Million USD | -7456.882% |
| Prenetics Global Limited | 44.01 Million USD | -7456.882% |
| Precipio, Inc. | 3.67 Million USD | -90478.132% |
| Personalis, Inc. | 95.65 Million USD | -3377.0% |
| RadNet, Inc. | 2.07 Billion USD | -60.419% |
| Sera Prognostics, Inc. | 25.28 Million USD | -13055.199% |
| Sotera Health Company | 2.68 Billion USD | -23.797% |
| Neuronetics, Inc. | 81.64 Million USD | -3973.969% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -15245.001% |
| Star Equity Holdings, Inc. | 21.67 Million USD | -15245.001% |
| Trinity Biotech plc | 83.38 Million USD | -3888.81% |
| T2 Biosystems, Inc. | 62.83 Million USD | -5193.443% |
| Twist Bioscience Corporation | 152.97 Million USD | -2074.287% |
| Exagen Inc. | 34.25 Million USD | -9611.034% |